Navellier & Associates’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-596
| Closed | -$335K | – | 358 |
|
|
2026
Q1 | $335K | Sell |
596
-7,199
| -92% | -$4.62M | 0.03% | 271 |
|
|
2025
Q4 | $5.27M | Buy |
+7,795
| New | +$5.31M | 0.59% | 42 |
|
|
2024
Q2 | – | Sell |
-373
| Closed | -$201K | – | 353 |
|
|
2024
Q1 | $201K | Hold |
373
| – | – | 0.02% | 327 |
|
|
2023
Q4 | $207K | Buy |
+373
| New | +$175K | 0.03% | 305 |
|
|
2022
Q2 | – | Sell |
-1,245
| Closed | -$681K | – | 302 |
|
|
2022
Q1 | $681K | Sell |
1,245
-17,688
| -93% | -$9.3M | 0.12% | 155 |
|
|
2021
Q4 | $12.5M | Buy |
18,933
+2,032
| +12% | +$1.28M | 1.81% | 6 |
|
|
2021
Q3 | $10.5M | Sell |
16,901
-7
| -0% | -$4.7K | 1.58% | 8 |
|
|
2021
Q2 | $10.7M | Buy |
16,908
+4
| +0% | +$2.21K | 1.61% | 7 |
|
|
2021
Q1 | $8.27M | Sell |
16,904
-353
| -2% | -$177K | 1.49% | 8 |
|
|
2020
Q4 | $8.63M | Buy |
17,257
+16,480
| +2,121% | +$7.37M | 1.56% | 10 |
|
|
2020
Q3 | $305K | Sell |
777
-600
| -44% | -$222K | 0.07% | 184 |
|
|
2020
Q2 | $455K | Sell |
1,377
-89
| -6% | -$25.8K | 0.11% | 141 |
|
|
2020
Q1 | $355K | Buy |
1,466
+63
| +4% | +$16.4K | 0.08% | 162 |
|
|
2019
Q4 | $366K | Sell |
1,403
-109
| -7% | -$28.7K | 0.06% | 218 |
|
|
2019
Q3 | $411K | Buy |
1,512
+12
| +0.8% | +$3.34K | 0.07% | 194 |
|
|
2019
Q2 | $413K | Sell |
1,500
-11,968
| -89% | -$2.95M | 0.06% | 195 |
|
|
2019
Q1 | $3.01M | Sell |
13,468
-935
| -6% | -$193K | 0.47% | 59 |
|
|
2018
Q4 | $2.68M | Sell |
14,403
-1,764
| -11% | -$362K | 0.46% | 51 |
|
|
2018
Q3 | $4.04M | Buy |
16,167
+130
| +0.8% | +$31.6K | 0.52% | 52 |
|
|
2018
Q2 | $3.5M | Buy |
16,037
+135
| +0.8% | +$27.8K | 0.49% | 53 |
|
|
2018
Q1 | $3.04M | Sell |
15,902
-7,443
| -32% | -$1.37M | 0.46% | 60 |
|
|
2017
Q4 | $3.65M | Sell |
23,345
-38,206
| -62% | -$6.01M | 0.68% | 45 |
|
|
2017
Q3 | $9.57M | Sell |
61,551
-114
| -0.2% | -$18K | 1.86% | 11 |
|
|
2017
Q2 | $9.95M | Sell |
61,665
-11,246
| -15% | -$1.83M | 1.49% | 12 |
|
|
2017
Q1 | $11.3M | Sell |
72,911
-8,807
| -11% | -$1.21M | 1.64% | 10 |
|
|
2016
Q4 | $9.58M | Buy |
81,718
+40,022
| +96% | +$4.57M | 1.58% | 6 |
|
|
2016
Q3 | $4.7M | Buy |
+41,696
| New | +$4.39M | 0.67% | 53 |
|
Other funds holding IDXX
Navellier & Associates's IDXX Position: Q2 2026 in Review
Navellier & Associates sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 596 shares — an estimated $335K sold.
Navellier & Associates first reported a position in IDXX in Q3 2016 and held it in 27 quarters. The position peaked at $12.5M in Q4 2021. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Navellier & Associates reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
- Navellier & Associates sold 596 Idexx Laboratories shares in Q2 2026, an estimated $335K.
- Navellier & Associates first reported a position in Idexx Laboratories in Q3 2016 and held it in 27 quarters.
- Navellier & Associates's Idexx Laboratories position peaked at $12.5M in Q4 2021.
- 1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.